US Smoking Rates No Longer Falling, Due to More Young Smokers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 12
Volume 8
Issue 12

ATLANTA-Smoking rates among adults in the United States have dropped dramatically over the past 30 years, from 44% in 1965 to 25.5% in 1990, but now the rate seems to have leveled off, the Centers for Disease Control and Prevention (CDC) said in a report.

ATLANTA—Smoking rates among adults in the United States have dropped dramatically over the past 30 years, from 44% in 1965 to 25.5% in 1990, but now the rate seems to have leveled off, the Centers for Disease Control and Prevention (CDC) said in a report.

The 1997 rate is 24.7%, exactly the same as the 1995 rate. The 1997 figure, based on a CDC survey of more than 35,000 people nationwide, translates into 48 million smokers.

The CDC noted that for most adult age groups, smoking rates did decline from 1990 to 1997, but this was countered by an increased smoking rate among adults aged 18 to 24 (from 24.5% in 1990 to 28.7% in 1997).

CDC officials are optimistic that smoking rates will decline in 1999 as a result of the recent cigarette price hike. However, the CDC expects to fall far short of its stated goal of reducing the adult smoking rate to 15% by the year 2000.

Articles in this issue
SWOG to Study Docetaxel/Estramustine in Advanced Prostate Cancer
US Smoking Rates No Longer Falling, Due to More Young Smokers
Americans Favor Higher Cigarette Tax to Balance the Budget
Saint Vincents Hospital Opens Comprehensive Cancer Center
New Breast Biopsy Techniques Allow ‘One-Stop’ Procedures
Director of NCI Mentioned as a Candidate to Head NIH
Challenges in Designing Chemoprevention Trials
Black Women Underrepresented in Breast Cancer Trials
UnitedHealthcare Plan Gives Physicians Final Say on Care
New Agents, Sequential Schedules Hold Promise
Half-Day Workshop Can Improve Cancer Team’s Communication Skills
The Search for Better SERMs Continues
Four SPORE Grants Will Support Ovarian Cancer Research
$70 Million Will Fund Tobacco Study Centers at Seven Universities
Cancer Risk of Veterans Exposed to Nuclear Weapons Tests Unresolved
Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Related Content
The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite stable mCRC.

Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer

Tim Cortese
October 27th 2025
Article

The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite stable mCRC.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population

Caroline Seymour
October 26th 2025
Article

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

PET-adapted strategies enhance treatment for advanced classical Hodgkin lymphoma, optimizing outcomes through individualized escalation and de-escalation based on PET results.

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era

Wael Abdulla Moh Khair, MD
October 26th 2025
Article

Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC

Russ Conroy
October 25th 2025
Article

Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.